261 related articles for article (PubMed ID: 29808997)
1. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
Huang KW; Lai YT; Chern GJ; Huang SF; Tsai CL; Sung YC; Chiang CC; Hwang PB; Ho TL; Huang RL; Shiue TY; Chen Y; Wang SK
Biomacromolecules; 2018 Jun; 19(6):2330-2339. PubMed ID: 29808997
[TBL] [Abstract][Full Text] [Related]
2. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.
Wu JY; Wang ZX; Zhang G; Lu X; Qiang GH; Hu W; Ji AL; Wu JH; Jiang CP
Int J Nanomedicine; 2018; 13():1265-1280. PubMed ID: 29551896
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
4. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
[TBL] [Abstract][Full Text] [Related]
5. Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma.
Shi B; Abrams M; Sepp-Lorenzino L
J Histochem Cytochem; 2013 Dec; 61(12):901-9. PubMed ID: 23979840
[TBL] [Abstract][Full Text] [Related]
6. Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy.
Wang X; Wu F; Li G; Zhang N; Song X; Zheng Y; Gong C; Han B; He G
Acta Biomater; 2018 Jul; 74():414-429. PubMed ID: 29787814
[TBL] [Abstract][Full Text] [Related]
7. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
Han L; Tang C; Yin C
Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049
[TBL] [Abstract][Full Text] [Related]
8. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Liu JY; Chiang T; Liu CH; Chern GG; Lin TT; Gao DY; Chen Y
Mol Ther; 2015 Nov; 23(11):1772-1782. PubMed ID: 26278330
[TBL] [Abstract][Full Text] [Related]
9. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer.
Perrone F; Craparo EF; Cemazar M; Kamensek U; Drago SE; Dapas B; Scaggiante B; Zanconati F; Bonazza D; Grassi M; Truong N; Pozzato G; Farra R; Cavallaro G; Grassi G
J Control Release; 2021 Feb; 330():1132-1151. PubMed ID: 33212117
[TBL] [Abstract][Full Text] [Related]
11. A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery.
Zou Y; Guo CG; Yang ZG; Sun JH; Zhang MM; Fu CY
Drug Des Devel Ther; 2016; 10():1243-55. PubMed ID: 27069355
[TBL] [Abstract][Full Text] [Related]
12. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma.
Xiong Q; Cui M; Bai Y; Liu Y; Liu D; Song T
Colloids Surf B Biointerfaces; 2017 Jul; 155():93-103. PubMed ID: 28411478
[TBL] [Abstract][Full Text] [Related]
13. A novel galactose-PEG-conjugated biodegradable copolymer is an efficient gene delivery vector for immunotherapy of hepatocellular carcinoma.
Liu L; Zong ZM; Liu Q; Jiang SS; Zhang Q; Cen LQ; Gao J; Gao XG; Huang JD; Liu Y; Yao H
Biomaterials; 2018 Nov; 184():20-30. PubMed ID: 30195802
[TBL] [Abstract][Full Text] [Related]
14. Development of hybrid-type modified chitosan derivative nanoparticles for the intracellular delivery of midkine-siRNA in hepatocellular carcinoma cells.
Zhong J; Huang HL; Li J; Qian FC; Li LQ; Niu PP; Dai LC
Hepatobiliary Pancreat Dis Int; 2015 Feb; 14(1):82-9. PubMed ID: 25655295
[TBL] [Abstract][Full Text] [Related]
15. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
16. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy.
Yang Z; Duan J; Wang J; Liu Q; Shang R; Yang X; Lu P; Xia C; Wang L; Dou K
Int J Nanomedicine; 2018; 13():1851-1865. PubMed ID: 29618926
[TBL] [Abstract][Full Text] [Related]
17. Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma.
Xue WJ; Feng Y; Wang F; Guo YB; Li P; Wang L; Liu YF; Wang ZW; Yang YM; Mao QS
Sci Rep; 2016 Feb; 6():22149. PubMed ID: 26915683
[TBL] [Abstract][Full Text] [Related]
18. Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA.
Sonoke S; Ueda T; Fujiwara K; Kuwabara K; Yano J
Biol Pharm Bull; 2011; 34(8):1338-42. PubMed ID: 21804229
[TBL] [Abstract][Full Text] [Related]
19. Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.
Wang K; Kievit FM; Sham JG; Jeon M; Stephen ZR; Bakthavatsalam A; Park JO; Zhang M
Small; 2016 Jan; 12(4):477-87. PubMed ID: 26641029
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and biocompatibility of glycyrrhetinic acid and galactose-modified chitosan nanoparticles as a novel targeting vehicle for hepatocellular carcinoma.
Li M; Wang Y; Jiang S; Gao Y; Zhang W; Hu S; Cheng X; Zhang C; Sun P; Ke W; Wang G; Song Z; Zhang Y; Zheng QC
Nanomedicine (Lond); 2020 Jan; 15(2):145-161. PubMed ID: 31782335
[No Abstract] [Full Text] [Related]
[Next] [New Search]
